832741-06-7

Basic information

• Product Name: Ethyl 6-Methylpyrazolo[1,5-A]Pyrimidine-3-Carboxylate
• Synonyms: Ethyl 6-Methylpyrazolo[1,5-A]Pyrimidine-3-Carboxylate
• CAS NO: 832741-06-7
• Molecular Formula: C10H11N3O2
• Molecular Weight: 205.21324
• Mol File: 832741-06-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 6-Methylpyrazolo[1,5-A]Pyrimidine-3-Carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6-Methylpyrazolo[1,5-A]Pyrimidine-3-Carboxylate(832741-06-7)
• EPA Substance Registry System: Ethyl 6-Methylpyrazolo[1,5-A]Pyrimidine-3-Carboxylate(832741-06-7)

Safety Data

• Hazardous Substances Data: 832741-06-7(Hazardous Substances Data)

Upstream product

• 62055-46-3 3-ethoxy-2-methylacrolein 
• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 
• 1260243-04-6 ethyl 5-amino-1H-pyrazole-4-carboxylate 
• 42588-57-8 3-ethoxymethacrolein 
• 10602-37-6 1,1,3,3-tetraethoxy-2-methyl-propane 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE

The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders

Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimization and enable validation of the physiological function of PDE2A in vivo, structural modifications of the high-throughput screening hit 18 were performed. Our lead generation efforts revealed three key potency-enhancing functionalities with minimal increases in molecular weight (MW) and no change in topological polar surface area (TPSA). Combining these structural elements led to the identification of 6-methyl-N-((1R)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (38a), a molecule with the desired balance of preclinical properties. Further characterization by cocrystal structure analysis of 38a bound to PDE2A uncovered a unique binding mode and provided insights into its observed potency and PDE selectivity. Compound 38a significantly elevated 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brain following oral administration, thus validating this compound as a useful pharmacological tool and an attractive lead for future optimization.

HETEROCYCLIC COMPOUND

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.